Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

zirconium Zr 89-ss-pertuzumab

A radioimmunoconjugate composed of pertuzumab, a humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the tyrosine kinase receptor human epidermal growth factor-2 (HER2; HER-2), and linked, using a site-specific bioconjugation method, to the radioisotope zirconium Zr 89 (Zr89), with potential use in the imaging of HER-2-expressing tumor cells upon positron emission tomography (PET). Upon administration of zirconium Zr 89-ss-pertuzumab, the pertuzumab moiety targets and binds to HER-2. After binding and internalization into HER-2-expressing tumor cells, Zr89 facilitates the visualization and detection of HER-2-expressing tumor cells using PET. This assesses HER2-expression and may predict or evaluate the tumor's response to certain HER-2-targeting chemotherapeutics. Site-specific bioconjugation may produce better defined and more homogeneous radioimmunoconjugates.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:89Zr-ss-pertuzumab
site-specifically-labeled 89Zr-pertuzumab
Zr 89-ss-pertuzumab
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search